Table 3 Comparison of FEV1 and SGRQ at baseline and at first and sustained clinically important deterioration between the glycopyrronium and tiotropium treatment groups

From: Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials

Deterioration

Glycopyrronium

Tiotropium

P value

First CID

 FEV1 (L)

N = 715

N = 404

 

 At baseline

1.47 ± 0.481

1.50 ± 0.527

0.3045

 At time of first CID

1.29 ± 0.466

1.32 ± 0.501

0.3452

 SGRQ (Units)

N = 432

N = 249

 

 At baseline

43.42 ± 16.791

43.33 ± 16.928

0.9497

 At time of first CID

53.92 ± 16.87

57.74 ± 17.47

0.3903

Sustained CID

 FEV1 (L)

N = 531

N = 296

 

 At baseline

1.50 ± 0.482

1.51 ± 0.534

0.7356

 At time of sustained CID

1.33 ± 0.480

1.33 ± 0.499

0.9184

 SGRQ (Units)

N = 104

N = 64

 

 At baseline

43.09 ± 16.914

43.11 ± 18.328

0.9947

 At time of sustained CID

54.02 ± 17.5

52.36 ± 18.18

0.5617

  1. Data are presented as mean ± standard deviation
  2. FEV 1 forced expiratory volume in 1 second, SGRQ St George’s Respiratory Questionnaire, CID clinically important deterioration, N number of patients
Back to article page